Vaccine and vaccination as a part of human life: In view of COVID‐19

Abstract

Background Vaccination created a great breakthrough toward the improvement to the global health. The development of vaccines and their use made a substantial decrease and control in infectious diseases. The abundance and emergence of new vaccines has facilitated targeting populations to alleviate and eliminate contagious pathogens from their innate reservoir. However, along with the infections like malaria and HIV, effective immunization remains obscure and imparts a great challenge to science. Purpose and scope The novel Corona virus SARS‐CoV‐2 is the reason for the 2019 COVID‐19 pandemic in the human global population, in the first half of 2019. The need for establishing a protected and compelling COVID‐19 immunization is a global prerequisite to end this pandemic. Summary and conclusion The different vaccine technologies like inactivation, attenuation, nucleic acid, viral vector, subunit, and viral particle based techniques are employed to develop a safe and highly efficient vaccine. The progress in vaccine development for SARS‐CoV2 is much faster in the history of science. Even though there exist of lot of limitations, continuous efforts has put forward so as to develop highly competent and effective vaccine for many human and animal linked diseases due to its unlimited prospective. This review article focuses on the historical outlook and the development of the vaccine as it is a crucial area of research where the life of the human is saved from various potential diseases.

Platform for Active Vaccine Formulation Using a Two-Mode Enhancement Mechanism of Epitope Presentation by Pickering Emulsion

“…The recent emergence of the SARS-CoV-2 pandemic has emphasized the need for rapid vaccine development strategies, which can be readily adapted to pathogen variations and to specific pathogen-related needs. The current SARS-CoV-2 vaccine technologies can be classified into two main categories: (i) nucleic-acid-based vaccines, which include mRNAs and DNA plasmids that encode viral antigenic proteins produced by the host cells, as well as viral vector-based vaccines and attenuated live-viruses, and (ii) protein-based vaccines, which are based on the presentation of antigenic viral peptides, as well as inactivated whole virus and subunit vaccines. − …”